
Alimera Sciences ALIM
Quartalsbericht 2024-Q2
hinzugefügt 07.08.2024
Alimera Sciences EV 2011-2026 | ALIM
EV Jährlich Alimera Sciences
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 197 M | 70.4 M | 13.3 M | 83.8 M | 77.8 M | 42.3 M | 26.2 M | 17.8 M | 19.9 M | -2.18 M | 25.6 M | -32.3 M | -20.7 M |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 197 M | -32.3 M | 39.9 M |
EV anderer Aktien in der Arzneimittelhersteller
| Name | EV | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
Avadel Pharmaceuticals plc
AVDL
|
756 M | $ 21.49 | -0.07 % | $ 2.04 B | ||
|
Adamis Pharmaceuticals Corporation
ADMP
|
28.5 M | - | 0.86 % | $ 117 M | ||
|
Aerie Pharmaceuticals
AERI
|
737 M | - | - | $ 754 M | ||
|
Agile Therapeutics
AGRX
|
25.3 M | - | 10.11 % | $ 58.2 M | ||
|
Canopy Growth Corporation
CGC
|
459 M | $ 1.21 | -2.03 % | $ 130 M | ||
|
AcelRx Pharmaceuticals
ACRX
|
23.6 M | - | 7.5 % | $ 6.35 M | ||
|
Cronos Group
CRON
|
3.84 B | $ 2.7 | 0.56 % | $ 1.43 B | ||
|
DURECT Corporation
DRRX
|
3.37 M | - | - | $ 50.1 M | ||
|
Calliditas Therapeutics AB (publ)
CALT
|
10.2 M | - | -0.1 % | $ 2.03 B | ||
|
HEXO Corp.
HEXO
|
284 M | - | 2.45 % | $ 38.1 M | ||
|
Catalent
CTLT
|
16.7 B | - | - | $ 11.5 B | ||
|
Emergent BioSolutions
EBS
|
1.2 B | $ 12.36 | -4.7 % | $ 633 M | ||
|
Eagle Pharmaceuticals
EGRX
|
457 M | - | -39.89 % | $ 27.7 M | ||
|
Endo International plc
ENDP
|
-710 M | - | - | $ 28.9 M | ||
|
Evoke Pharma
EVOK
|
7.15 M | - | - | $ 36.6 M | ||
|
Athenex
ATNX
|
209 M | - | -23.39 % | $ 1.76 M | ||
|
Zomedica Corp.
ZOM
|
137 M | - | -0.21 % | $ 98 M | ||
|
Rockwell Medical
RMTI
|
57.3 M | $ 0.97 | 3.37 % | $ 22.6 M | ||
|
Evolus
EOLS
|
1.03 B | $ 5.6 | -0.88 % | $ 347 M | ||
|
Harrow Health
HROW
|
515 M | $ 44.87 | -4.08 % | $ 1.46 B | ||
|
China Pharma Holdings
CPHI
|
11.1 M | $ 1.31 | - | $ 22.9 M | ||
|
Zynerba Pharmaceuticals
ZYNE
|
-22.6 M | - | - | $ 55.5 M | ||
|
Jupiter Wellness
JUPW
|
91.9 M | - | - | $ 33.6 M | ||
|
OrganiGram Holdings
OGI
|
456 M | $ 1.69 | -1.74 % | $ 402 M | ||
|
Organogenesis Holdings
ORGO
|
392 M | $ 4.12 | -2.26 % | $ 542 M | ||
|
Bausch Health Companies
BHC
|
29.9 B | $ 7.41 | -0.13 % | $ 2.7 B | ||
|
Lannett Company
LCI
|
648 M | - | 1.15 % | $ 7.11 M | ||
|
Cumberland Pharmaceuticals
CPIX
|
124 M | $ 4.93 | -0.3 % | $ 69.3 M | ||
|
Sundial Growers
SNDL
|
-2.47 M | $ 1.66 | -0.09 % | $ 3.37 M | ||
|
Sonoma Pharmaceuticals
SNOA
|
7.57 M | $ 3.52 | -3.46 % | $ 4.37 M | ||
|
Neoleukin Therapeutics
NLTX
|
-110 M | - | - | $ 193 M | ||
|
Tilray
TLRY
|
1.96 B | $ 8.96 | -2.4 % | $ 5.54 B | ||
|
Aurora Cannabis
ACB
|
106 M | $ 4.2 | -0.81 % | $ 86.3 M | ||
|
Pacira BioSciences
PCRX
|
1.68 B | $ 23.4 | -0.55 % | $ 1.08 B | ||
|
Veru
VERU
|
111 M | $ 2.35 | -1.88 % | $ 317 M | ||
|
PetIQ
PETQ
|
280 M | - | 1.64 % | $ 400 M | ||
|
ProPhase Labs
PRPH
|
145 M | - | - | $ 5.07 M | ||
|
Perrigo Company plc
PRGO
|
8.73 B | $ 14.9 | -1.16 % | $ 2.05 B | ||
|
Radius Health
RDUS
|
700 M | - | - | $ 1.42 B | ||
|
Recro Pharma
REPH
|
220 M | - | -4.76 % | $ 65.3 M | ||
|
Relmada Therapeutics
RLMD
|
170 M | $ 4.34 | 0.7 % | $ 131 M | ||
|
OptiNose
OPTN
|
312 M | - | - | $ 1.08 B | ||
|
Assertio Holdings
ASRT
|
141 M | $ 9.22 | 0.27 % | $ 655 M | ||
|
PLx Pharma
PLXP
|
73.8 M | - | -27.8 % | $ 2.56 M | ||
|
Solid Biosciences
SLDB
|
197 M | $ 5.12 | -3.21 % | $ 209 M | ||
|
SCYNEXIS
SCYX
|
91.7 M | $ 0.66 | -2.05 % | $ 31.6 M | ||
|
Tricida
TCDA
|
506 M | - | - | $ 3.25 M | ||
|
TherapeuticsMD
TXMD
|
33.6 M | $ 2.13 | -1.39 % | $ 22.2 M | ||
|
Viatris
VTRS
|
41.3 B | $ 12.77 | 0.08 % | $ 15.5 B |